(STOK) Stoke Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.943m USD | Total Return: 419.7% in 12m

Stock Genetic Therapies, Antisense Oligonucleotides, Neurological Treatments
Total Rating 52
Safety 31
Buy Signal -0.33
Biotechnology +0.2
Biotechnology +1.0
Market Cap: 1,943m
Avg Trading Vol: 26.4M USD
ATR: 7.70%
Peers RS (IBD): 86.8
Risk 5d forecast
Volatility77.0%
Rel. Tail Risk-15.1%
Reward TTM
Sharpe Ratio2.58
Alpha329.95
Character TTM
Beta1.230
Beta Downside-0.441
Drawdowns 3y
Max DD75.62%
CAGR/Max DD0.79
EPS (Earnings per Share) EPS (Earnings per Share) of STOK over the last years for every Quarter: "2021-03": -0.46, "2021-06": -0.6, "2021-09": -0.61, "2021-12": -0.66, "2022-03": -0.66, "2022-06": -0.63, "2022-09": -0.66, "2022-12": -0.65, "2023-03": -0.53, "2023-06": -0.69, "2023-09": -0.55, "2023-12": -0.6, "2024-03": -0.57, "2024-06": -0.46, "2024-09": -0.4691, "2024-12": -0.18, "2025-03": 1.9, "2025-06": -0.4, "2025-09": -0.65, "2025-12": -0.97, "2026-03": 0,
EPS CAGR: 28.77%
EPS Trend: 31.8%
Last SUE: 1.06
Qual. Beats: 1
Revenue Revenue of STOK over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 3, 2022-06: 3.231, 2022-09: 2.905, 2022-12: 3.269, 2023-03: 5.152, 2023-06: -2.481, 2023-09: 3.308, 2023-12: 2.802, 2024-03: 4.216, 2024-06: 4.831, 2024-09: 4.894, 2024-12: 22.614, 2025-03: 158.569, 2025-06: 13.817, 2025-09: 10.632, 2025-12: 1.402, 2026-03: null,
Rev. CAGR: -18.36%
Rev. Trend: 41.0%
Last SUE: -0.10
Qual. Beats: 0
Risks
Technicals: volatile
Description: STOK Stoke Therapeutics

Stoke Therapeutics, Inc. (STOK) is an early-stage biopharmaceutical company focused on treating severe genetic diseases. It develops treatments by increasing protein expression.

The company employs its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform. This platform uses antisense oligonucleotides (ASOs) to restore protein levels. ASOs are a type of drug that can modulate gene expression.

STOKs lead product candidates include STK-002, in preclinical development for autosomal dominant optic atrophy, and Zorevunersen (STK-001), in Phase I/II clinical trials for Dravet syndrome. Dravet syndrome is a rare, severe form of epilepsy.

Stoke Therapeutics also has collaborations with Biogen Inc. for Zorevunersen and Acadia Pharmaceuticals Inc. for RNA-based medicines targeting genetic neurodevelopmental diseases. These partnerships are common in the biotechnology sector for sharing development costs and expertise.

Further research into their clinical trial data and market potential is recommended for a comprehensive understanding.

Headlines to Watch Out For
  • Zorevunersen (STK-001) clinical trial results impact stock
  • Biogen collaboration milestones drive revenue
  • STK-002 preclinical data influences future valuation
  • Regulatory approval for lead candidates critical for commercialization
  • Pipeline expansion into new genetic diseases diversifies risk
Piotroski VR‑10 (Strict) 3.0
Net Income: -6.88m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA 42.79 > 1.0
NWC/Revenue: 134.4% < 20% (prev 527.2%; Δ -392.8% < -1%)
CFO/TA 0.11 > 3% & CFO 45.6m > Net Income -6.88m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 5.28 > 1.5 & < 3
Outstanding Shares: last quarter (58.4m) vs 12m ago 2.38% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 53.46% > 50% (prev 13.46%; Δ 39.99% > 0%)
Interest Coverage Ratio: -5.91 > 6 (EBITDA TTM -14.2m / Interest Expense TTM 2.90m)
Altman Z'' -8.24
A: 0.59 (Total Current Assets 305.7m - Total Current Liabilities 57.9m) / Total Assets 418.4m
B: -1.19 (Retained Earnings -497.7m / Total Assets 418.4m)
C: -0.05 (EBIT TTM -17.1m / Avg Total Assets 345.0m)
D: -7.54 (Book Value of Equity -497.2m / Total Liabilities 66.0m)
Altman-Z'' Score: -8.24 = D
Beneish M 1.00
DSRI: 2.24 (Receivables 7.91m/700k, Revenue 184.4m/36.6m)
GMI: 0.90 (GM 97.73% / 87.85%)
AQI: 2.26 (AQ_t 0.25 / AQ_t-1 0.11)
SGI: 5.05 (Revenue 184.4m / 36.6m)
TATA: -0.13 (NI -6.88m - CFO 45.6m) / TA 418.4m)
Beneish M-Score: 1.42 (Cap -4..+1) = D
What is the price of STOK shares? As of April 05, 2026, the stock is trading at USD 32.56 with a total of 1,047,476 shares traded.
Over the past week, the price has changed by -0.33%, over one month by -3.08%, over three months by +0.58% and over the past year by +419.68%.
Is STOK a buy, sell or hold? Stoke Therapeutics has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy STOK.
  • StrongBuy: 7
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the STOK price?
Wallstreet Target Price 45.1 38.5%
Analysts Target Price 45.1 38.5%
STOK Fundamental Data Overview as of 05 April 2026
P/E Forward = 204.0816
P/S = 10.5363
P/B = 5.513
Revenue TTM = 184.4m USD
EBIT TTM = -17.1m USD
EBITDA TTM = -14.2m USD
Long Term Debt = 3.01m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.91m USD (from shortTermDebt, two quarters ago)
Debt = 2.91m USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -84.2m USD (from netDebt column, last quarter)
Enterprise Value = 1.66b USD (1.94b + Debt 2.91m - CCE 284.7m)
Interest Coverage Ratio = -5.91 (Ebit TTM -17.1m / Interest Expense TTM 2.90m)
EV/FCF = 36.99x (Enterprise Value 1.66b / FCF TTM 44.9m)
FCF Yield = 2.70% (FCF TTM 44.9m / Enterprise Value 1.66b)
FCF Margin = 24.35% (FCF TTM 44.9m / Revenue TTM 184.4m)
Net Margin = -3.73% (Net Income TTM -6.88m / Revenue TTM 184.4m)
 Gross Margin = unknown ((Revenue TTM 184.4m - Cost of Revenue TTM 4.18m) / Revenue TTM)
 Tobins Q-Ratio = 3.97 (Enterprise Value 1.66b / Total Assets 418.4m)
Interest Expense / Debt = 0.10% (Interest Expense 3.00k / Debt 2.91m)
Taxrate = 21.0% (US default 21%)
NOPAT = -13.5m (EBIT -17.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.28 (Total Current Assets 305.7m / Total Current Liabilities 57.9m)
Debt / Equity = 0.01 (Debt 2.91m / totalStockholderEquity, last quarter 352.5m)
 Debt / EBITDA = 5.95 (negative EBITDA) (Net Debt -84.2m / EBITDA -14.2m)
 Debt / FCF = -1.88 (Net Debt -84.2m / FCF TTM 44.9m)
Total Stockholder Equity = 336.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.00% (Net Income -6.88m / Total Assets 418.4m)
RoE = -2.05% (Net Income TTM -6.88m / Total Stockholder Equity 336.4m)
RoCE = -5.04% (EBIT -17.1m / Capital Employed (Equity 336.4m + L.T.Debt 3.01m))
 RoIC = -4.02% (negative operating profit) (NOPAT -13.5m / Invested Capital 336.4m)
 WACC = 10.29% (E(1.94b)/V(1.95b) * Re(10.31%) + D(2.91m)/V(1.95b) * Rd(0.10%) * (1-Tc(0.21)))
Discount Rate = 10.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.96%
[DCF] Terminal Value 70.31% ; FCFF base≈44.9m ; Y1≈44.5m ; Y5≈46.3m
[DCF] Fair Price = 11.05 (EV 569.1m - Net Debt -84.2m = Equity 653.3m / Shares 59.2m; r=10.29% [WACC]; 5y FCF grow -1.77% → 3.0% )
EPS Correlation: 31.76 | EPS CAGR: 28.77% | SUE: 1.06 | # QB: 1
Revenue Correlation: 40.98 | Revenue CAGR: -18.36% | SUE: -0.10 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.81 | Chg7d=-0.072 | Chg30d=-0.039 | Revisions Net=-3 | Analysts=9
EPS current Year (2026-12-31): EPS=-3.37 | Chg7d=-0.248 | Chg30d=-0.262 | Revisions Net=-5 | Growth EPS=-2706.7% | Growth Revenue=-85.3%
EPS next Year (2027-12-31): EPS=-3.18 | Chg7d=-0.475 | Chg30d=-0.685 | Revisions Net=-4 | Growth EPS=+5.7% | Growth Revenue=+81.3%
[Analyst] Revisions Ratio: -0.43 (2 Up / 5 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle